High levels of circulating miR-19a-3p in patients with metastatic HER2 + breast cancer are associated with a favorable prognosis and anti-tumor immune responses
Our findings suggest that elevated levels of miR-19a-3p in the serum of patients with HER2 + metastatic breast cancer may result from effective NK cell-mediated ADCC and activation of CD4 + Th1 cells, which could be responsible for the anti-tumor immune response associated with a favorable prognosis. Blood levels of miR-19a-3p might help identify breast cancer patients who have effective trastuzumab-induced anti-tumor immune responses.
Authors
- Naoto Takahashi (ORCID: https://orcid.org/0000-0002-2353-4430)
- C. Ivan
- Evan N. Cohen (ORCID: https://orcid.org/0000-0003-4192-9644)
- Qiong Wu (ORCID: https://orcid.org/0009-0006-9223-2467)
- Sanda Tin
- James M. Reuben
- Hui Gao
- Simone Anfossi
- Wendy A. Woodward
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Cancer Center of Hawaii (US)
- Caris Life Sciences (United States) (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2026-01-25
- DOI
- https://doi.org/10.1186/s13058-025-02174-8
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
- National Cancer Institute